Related Experiment Video
Updated: Aug 11, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Percutaneous closure of patent foramen ovale with amplatzer device. Report of two cases]
Jaime E Munayer Calderón1, Gerardo Maza Juárez, Juan Carlos Carpio
1Servicio de Hemodinamia Pediátrica HG CMN La Raza, Hospital General Centro Médico La Raza, Dpto. Hemodinámica, México. munayerjaime90@hotmail.com
Insights
Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer devices effectively treated two patients with a history of cerebrovascular accidents. Both individuals remained asymptomatic post-procedure, highlighting the device
Area of Science:
- Cardiology
- Interventional Cardiology
- Neurology
Background:
- Patent Foramen Ovale (PFO) is a potential risk factor for cerebrovascular accidents.
- Management of PFO in patients with neurological events remains a clinical challenge.
Observation:
- Two cases of PFO are presented: a 48-year-old woman with Ebstein's disease and multiple cerebrovascular accidents, and a 22-year-old man with a history of cerebrovascular accident and seizures.
- Both patients experienced significant hemodynamic compromise and neurological sequelae despite medical management.
Findings:
- Percutaneous closure of PFO was successfully performed in both patients using Amplatzer devices.
- The first patient received a foramen ovale device, while the second received a septal occluder due to anatomical variations.
- Both patients remained asymptomatic during the follow-up period after device implantation.
Implications:
- Percutaneous PFO closure with Amplatzer devices is a viable treatment option for select patients with a history of cerebrovascular accidents.
- This approach offers a minimally invasive solution for preventing recurrent neurological events in PFO patients.
- Further research is warranted to establish long-term efficacy and patient selection criteria.
Objective:
We present two cases of Patent Foramen Ovale (PFO) treated with percutaneous Amplatzer device.
Method:
The first case corresponds to 48 years old woman with Ebstein's disease with moderate to severe hemodynamic repercussion and three cerebrovascular accidents, the last one under coumarin treatment, she received antiarrhythmic medication and despite of it developed 1st degree AV block, supraventricular and ventricular ectopia, rigth branch block. The second case corresponds to a 22 years old man with antecedents of cerebrovascular accident at the age of 21 with sequelae of convulsive crisis. Both patients were percutaneously treated with Amplatzer devices. The first patient was treated with a foramen ovale device and second with septal occluder due to the diameter of the foramen. Both patients have remained asymptomatic during the follow-up period.
Conclusions:
The PFO devices are indicated for patients with a history of cerebrovascular accidents.
